Synthetic Nanofiber-Reinforced Amniotic Membrane via Interfacial Bonding,ACS Applied Materials & Interfaces

当前位置： X-MOL 学术 › ACS Appl. Mater. Interfaces › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Synthetic Nanofiber-Reinforced Amniotic Membrane via Interfacial Bonding
ACS Applied Materials & Interfaces ( IF 8.3 ) Pub Date : 2018-04-03 00:00:00 , DOI: 10.1021/acsami.8b03087
Huanhuan Liu , Zhengbing Zhou ₁ , Hui Lin , Juan Wu ₂ , Brian Ginn , Ji Suk Choi , Xuesong Jiang , Liam Chung ₃ , Jennifer H. Elisseeff ₃ , Samuel Yiu , Hai-Quan Mao ₃

Affiliation

Severe damage to the ocular surface can result in limbal stem cell (LSC) deficiency, which contributes to loss of corneal clarity, potential vision loss, chronic pain, photophobia, and keratoplasty failure. Human amniotic membrane (AM) is the most effective substrate for LSC transplantation to treat patients with LSC deficiency. However, the widespread use of the AM in the clinic remains a challenge because of the high cost for preserving freshly prepared AM and the weak mechanical strength of lyophilized AM. Here, we developed a novel composite membrane consisting of an electrospun bioabsorbable polymer fiber mesh bonded to a decellularized AM (dAM) sheet through interfacial conjugation. This membrane engineering approach drastically improved the tensile property and toughness of dAM, preserved similar levels of bioactivities as the dAM itself in supporting LSC attachment, growth, and maintenance, and retained significant anti-inflammatory capacity. These results demonstrate that the lyophilized nanofiber–dAM composite membrane offers superior mechanical properties for easy handling and suturing to the dAM, while presenting biochemical cues and basement membrane structure to facilitate LSC transplantation. This composite membrane exhibits major advantages for clinical applications in treating soft tissue damage and LSC deficiency.

中文翻译：

通过界面键合合成的纳米纤维增强羊膜

对眼表的严重损害会导致角膜缘干细胞（LSC）缺乏，从而导致角膜清晰度丧失，潜在的视力丧失，慢性疼痛，畏光和角膜移植失败。人羊膜（AM）是LSC移植治疗LSC缺乏症患者的最有效基质。然而，由于保存新鲜制备的AM的高成本和冻干的AM的机械强度较弱，AM在临床上的广泛使用仍然是一个挑战。在这里，我们开发了一种新型复合膜，该复合膜由电纺生物可吸收聚合物纤维网组成，该纤维网通过界面共轭结合到脱细胞的AM（dAM）薄片上。这种膜工程方法极大地改善了dAM的拉伸性能和韧性，在支持LSC附着，生长和维持方面，与dAM本身保持相似水平的生物活性，并保留了显着的抗炎能力。这些结果表明，冻干的纳米纤维-dAM复合膜具有出色的机械性能，易于处理和缝合至dAM，同时具有生化线索和基底膜结构，可促进LSC移植。这种复合膜在治疗软组织损伤和LSC缺乏症方面具有临床应用的主要优势。同时提供生化线索和基底膜结构，以促进LSC移植。这种复合膜在治疗软组织损伤和LSC缺乏症方面具有临床应用的主要优势。同时呈现生化线索和基底膜结构，以促进LSC移植。这种复合膜在治疗软组织损伤和LSC缺乏症方面具有临床应用的主要优势。

更新日期：2018-04-03

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11